Critical Care

, 12:P401 | Cite as

Meta-analysis of dopexamine and its effect on mortality in patients undergoing major surgery

  • D Jayakumar
  • S Gopal
Poster presentation


Clinical Trial Systematic Review Relative Risk Random Effect Hydrochloride 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Dopexamine hydrochloride is a synthetic dopaminergic agent with predominant DA-1 and β-2 agonist properties. Studies using dopexamine in the perioperative period have yielded conflicting results. One published systematic review discussed only the effect of dopexamine on renal and hepatosplanchnic perfusion. Hence, we conducted a meta-analysis to investigate the effect of dopexamine on mortality in patients undergoing major abdominal surgery.


Embase (1974–July 2007), Medline (1950–July 2007), CINAHL, PubMed, and CENTRAL were searched using the MeSH term 'Dopexamine'. Four out of the 42 potentially eligible studies fulfilled the inclusion criteria. A total of 851 patients were included in these four studies. The data were pooled and entered into Revman 4.2 for further analysis. A random effects model was used and the results are reported as relative risks (RR) with 95% CI.


Mortality was not significantly different with dopexamine treatment (RR = 0.61, 95% CI = 0.32–1.18; P = 0.14). Subgroup analysis involving the studies that used low-dose (≤ 1 μg/kg/min) dopexamine failed to show any benefit. See Figure 1.

Figure 1


Dopexamine does not improve mortality in patients undergoing major abdominal surgery. The benefits of a particular dose of administration remain uncertain because of the limited number of studies included in this meta-analysis. Further well-powered multicentre randomised controlled clinical trials will be needed to address this.


  1. 1.
    Stone MD, et al.: Br J Anaesth. 2003, 91: 619-624. 10.1093/bja/aeg245PubMedCrossRefGoogle Scholar
  2. 2.
    Wilson J, et al.: BMJ. 1999, 318: 1099-1103.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Boyd O, et al.: JAMA. 1993, 270: 2699-2707. 10.1001/jama.270.22.2699PubMedCrossRefGoogle Scholar
  4. 4.
    Takala J, et al.: Crit Care Med. 2000, 28: 3417-3423. 10.1097/00003246-200010000-00007PubMedCrossRefGoogle Scholar

Copyright information

© BioMed Central Ltd 2008

This article is published under license to BioMed Central Ltd.

Authors and Affiliations

  • D Jayakumar
    • 1
  • S Gopal
    • 1
  1. 1.Royal Wolverhampton Hospitals NHS TrustWolverhamptonUK

Personalised recommendations